Bio-Rad (BIO) Q4 2025: Process Chromatography Slumps Mid-Teens, Margin Recovery Hinges on Operational Execution
Bio-Rad’s Q4 highlighted margin pressure and a pronounced process chromatography decline, while diagnostics and digital PCR provided offsetting momentum. Management’s candid assessment of operational missteps and cautious outlook for key segments signal a business in strategic transition, with margin recovery and portfolio optimization now central to the investment case. Investors should watch for tangible improvements in cost discipline and execution as Bio-Rad navigates sector headwinds and evolving end-market dynamics.
Summary
- Process Chromatography Downturn: Segment faces mid-teens decline as vaccine demand softens and bioprocess mix shifts.
- Diagnostics and Digital PCR Offset Weakness: Quality controls and QX700 adoption support growth amid academic and biopharma caution.
- Margin Rebuild in Focus: Operational discipline and portfolio reshaping are critical to restoring profitability in 2026.
Business Overview
Bio-Rad Laboratories is a global provider of life science research and clinical diagnostics products. The business operates two primary segments: Life Science, which supplies instruments, reagents, and consumables for research and bioprocessing, and Clinical Diagnostics, offering quality control, blood typing, and disease testing products for laboratories and hospitals. Revenue is driven by instrument sales, recurring consumables, and service contracts, with a growing focus on digital PCR (polymerase chain reaction) and bioprocessing solutions.
Performance Analysis
Bio-Rad delivered Q4 results within revised revenue and operating margin guidance, but gross margin missed expectations due to execution-related supply chain costs. The diagnostics segment was the growth engine, buoyed by strong quality control and blood typing sales across all regions. In contrast, life science revenue declined as academic and biotech funding remained constrained, especially in the Americas. The digital PCR (DDPCR) portfolio, led by the QX700 platform, achieved mid-single-digit growth, with instrument sales gaining share from both QPCR conversions and competitive wins.
Process chromatography, a niche bioprocessing business focused on the polishing step, suffered a notable drop due to changing vaccine demand and customer production efficiencies. This volatility, combined with higher-than-expected freight and service costs, weighed on overall margins. SG&A rose on higher employee costs, while R&D spend was down year-over-year, reflecting prior acquisition-related charges. Free cash flow improved sharply, aided by working capital discipline, even as operating income turned negative on GAAP due to impairment and rationalization charges.
- Diagnostics Outpaces Life Science: Clinical diagnostics grew 8% YoY in Q4, while life science declined 3% reported (4% currency-neutral).
- Gross Margin Compression: Non-GAAP gross margin fell to 52.5%, pressured by expedited logistics and delayed procurement savings.
- Process Chromatography Volatility: Segment’s mid-teens projected decline for 2026 highlights revenue concentration risk.
Share buybacks paused in Q4 after a $296 million repurchase for the year, and cash generation remained strong, supporting future capital allocation flexibility.
Executive Commentary
"In 2025, we delivered results within our revised guidance for both revenue and operating margin. However, gross margin did not meet our expectations, or frankly, what Bio-Rad is capable of delivering. Throughout 2025, we made tangible progress in lowering our cost base through restructuring and tighter expense discipline while navigating global trade uncertainty and tariff headwinds."
John DiVincenzo, President and Chief Operating Officer
"We do remain highly focused on driving long-term value and are already seeing the impact of an intentional performance-related approach. Kind of against the dynamic backdrop of last year, Bio-Rad delivered results that reflect both the challenges of the environment, but also I think the resilience of our business... Overall, I guess top of mind is driving continuous revenue growth and margin expansion through improved sustainable operating performance and cost structure management."
Norman Schwartz, Chief Executive Officer
Strategic Positioning
1. Margin Rebuild and Operational Discipline
Management is prioritizing operational rigor and cost structure improvement after Q4’s gross margin miss. Actions include strengthening forecasting, streamlining manufacturing, and accelerating procurement initiatives. The company expects these steps to yield sequential margin improvement through 2026, with Q1 gross margin projected to recover by 100 basis points as one-time Q4 costs abate.
2. Diagnostics as a Stabilizer
Diagnostics returned to growth, led by quality controls and blood typing products, providing a buffer against life science softness. Management remains cautious on China reimbursement and VBP (volume-based procurement) risk, but no new headwinds have materialized. The segment’s stability is central to Bio-Rad’s near-term revenue resilience.
3. Digital PCR Growth Platform
The QX700 droplet digital PCR platform is gaining traction, driving both competitive wins and QPCR conversions. The installed base supports recurring consumables revenue, and management sees digital PCR as a long-term growth pillar. The still acquisition is now expected to be accretive by mid-2026, ahead of schedule, reinforcing Bio-Rad’s leadership in this technology.
4. Process Chromatography Recalibration
A sharp reset in process chromatography guidance reflects changes in vaccine demand and customer manufacturing strategies. The business remains concentrated in a few commercial therapeutics, amplifying quarter-to-quarter volatility. Management expects broader portfolio development to reduce this lumpiness over time, but near-term declines are a material drag on growth and margin mix.
5. Portfolio Optimization and M&A Readiness
Bio-Rad is actively assessing its product portfolio and open to additional asset acquisitions, supported by a strong balance sheet and $1.5 billion in cash. The company is deferring its investor day to allow time for further transformation and strategic clarity.
Key Considerations
Bio-Rad’s Q4 and full-year results underscore a business in transition, balancing the drag from process chromatography and margin pressure with green shoots in diagnostics and digital PCR. The investment case now hinges on execution and the ability to translate operational discipline into sustainable margin recovery.
Key Considerations:
- Process Chromatography Drag: The mid-teens decline in 2026 guidance spotlights Bio-Rad’s revenue concentration and exposure to vaccine demand swings.
- Diagnostics Anchors Stability: Quality control and blood typing products are offsetting other portfolio headwinds, but growth remains muted versus pre-pandemic levels.
- Digital PCR as Growth Engine: QX700 success and installed base expansion underpin management’s confidence in long-term digital PCR market leadership.
- Margin Recovery Path: Operational improvements, cost discipline, and portfolio rationalization are essential to hitting 2026 margin targets.
- Capital Deployment Optionality: With $285 million left in the buyback authorization and ample cash, M&A and opportunistic repurchases remain viable levers.
Risks
Process chromatography’s concentration in vaccines and commercial therapeutics exposes Bio-Rad to outsized swings from customer demand shifts and regulatory changes. Academic and government funding uncertainty continues to weigh on life science instrument demand, while China reimbursement policy remains a latent risk for diagnostics. Margin recovery is contingent on flawless operational execution, and further supply chain or cost discipline lapses could undermine profitability. Ongoing portfolio rationalization and restructuring charges may create near-term volatility.
Forward Outlook
For Q1 2026, Bio-Rad guided to:
- Low single-digit revenue decline year-over-year, with sequential improvement expected each quarter
- Gross margin up 100 basis points from Q4 as one-time costs recede
For full-year 2026, management provided:
- Currency-neutral revenue growth of 0.5% to 1.5%
- Life science segment growth of 0% to 0.5%, with core life science (excluding process chromatography) up nearly 4%
- Process chromatography down mid-teens, diagnostics up 1% to 2%
- Non-GAAP gross margin of 54% to 54.5%
- Operating margin of 12% to 12.5%
- Free cash flow of $375 million to $395 million
Management stressed that operational improvements and portfolio optimization are the primary drivers for 2026 margin and growth targets. Process chromatography’s drag is expected to lessen over time, but near-term volatility will persist.
- Sequential margin improvement as cost initiatives take hold
- Continued focus on innovation and possible asset acquisitions
Takeaways
Bio-Rad’s Q4 punctuated a year of mixed execution, with diagnostics and digital PCR showing resilience but process chromatography and operational missteps weighing on results.
- Process Chromatography Overhang: The steep decline in this niche bioprocessing segment is a structural headwind, with recovery tied to portfolio broadening and end-market stabilization.
- Margin Rebuild Is Central: Gross margin improvement and SG&A control are now critical, especially as one-off Q4 costs fade and operational discipline is tested through 2026.
- Watch Digital PCR and M&A: The QX700’s momentum and management’s openness to acquisitions could reshape Bio-Rad’s growth profile if execution matches ambition.
Conclusion
Bio-Rad enters 2026 with a sharpened focus on operational discipline, portfolio optimization, and selective investment in growth platforms. While diagnostics and digital PCR provide a foundation, the process chromatography reset and margin pressures demand close monitoring. Sustained improvement in execution and cost structure will determine whether the business can deliver on its long-term value creation goals.
Industry Read-Through
Bio-Rad’s results reflect broader bioprocessing volatility as vaccine demand normalizes and customers drive production efficiencies. The margin compression and supply chain cost spikes are emblematic of sector-wide pressures facing life science tool providers. Digital PCR’s continued adoption, despite academic funding headwinds, signals enduring demand for high-sensitivity molecular tools, favoring players with broad assay menus and installed bases. Diagnostics’ resilience, anchored in quality controls, offers a template for others seeking recurring revenue stability amid end-market uncertainty. Overall, operational execution and cost discipline will be the differentiators for industry peers in a landscape marked by funding caution and shifting customer priorities.